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1. Introduction 
The epidermal growth factor receptor family consists of four members with similar 
structures: HER1/erbB1, HER2/erbB2, HER3/erbB3 and HER4/erbB4. The genes encoded 
for Erb are proto-oncogenes, or precursor genes, which under normal conditions are present 
in all cells of an organism. Proto-oncogenes can be activated in several ways, most often it is 
through structural changes of the cell genome such as point mutation, translocation or 
amplification (Ghaderi, 2002). 
These receptors play an important role in the processes of proliferation and differentiation 
of normal cells. Hence, any aberrations in their structure or function can be the cause of 
tumor development and progression. All members of the epidermal growth factor receptor 
family have a similar structure with an extracellular domain linking the ligand, 
transmembrane domain and intracytoplasmic domain of the tyrosine kinase. The binding of 
the ligand to these receptors causes the creation of homodimers and heterodimers as well as 
the activation of downstream signaling pathways (Ghaderi, 2002). The ligand by inducing 
extracellular homo and heterodimerization of the ErbB receptors undergoes auto- 
phosphorylation using intracellular tyrosine residues by arranging the tyrosine kinase 
domains next to each other. The phosphorylated tyrosine endings of the cytoplasmic 
receptor act as sites that bind different intracytoplasmic transduction particles, which 
participate in the cellular response depending on ErbB stimulation (Tvorogov 2009). For this 
reason the HER family can contribute to tumor progression. Most research has shown a high 
level expression of the HER family members in patients suffering from gastric cancers 
(Ghaderi, 2002). 
Signaling through the HER pathway plays a fundamental role in the regulation of correct 
cell growth, proliferation, migration and takes part in such processes like the healing of 
wounds, cell repair and skin maintenance. However, it has been shown that signaling 
through the HER pathway plays a very important role in the growth process, replication, 
migration and survival of cancer cells. Since the HER signaling pathway cascades, causing 
the strengthening of the growth signal on progressing levels, small changes in the amount or 
activity of EGRF can significantly accelerate the development or progression of the tumor by 
facilitating cell replication and migration, and suppression of the apoptosis process 
(programmed cell death). What is more, many studies have shown that HER signaling, a 
fundamental factor in correct cell growth and repair, can be activated as a response to 
different therapies used to treat cancer, like chemotherapy or radiation therapy, and can 
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lead to cell and tissue damage. It has been suggested that HER pathway activation can 
contribute to the development of resistance to cancer therapies (Zhou, 1992; Liang, 2003). 
Under normal conditions the activation of the EGFR family is controlled by spatial and 
periodic expression of its ligands, which belong to the EGF-related peptide growth family, 
such as EGF, heparin-binding EGF (HB-EGF), transforming growth factor alpha (TNF-α) 
and neuroregulin. These growth factors are synthesized as transmembrane precursors 
released from the cell surface by proteolytic cleavage and subsequently activate RTKs of the 
EGFR family in an autocrine or paracrine fashion. Despite the abundance of ligands 
identified for EGFR, ErbB3 and ErbB4, no direct ligand for HER2 has been discovered. 
Instead, HER2 functions as a homo or heterodimer with other members of the EGFR family 
through interaction with anonistic ligands, such as EGF, HB-EGF and TNF-α (Iwamoto, 
2006).  
Constant activation of receptor kinases leads to excessive activation of the signaling 
pathway. The causes of kinase over-expression can vary, mutations, autocrine kinase 
activation or amplification, for example. Elevated signal transfer activity can be connected to 
an increased risk of tumor development and malignancy (Walles, 1999). 
2. HER 1/ EGFR/ HERA/c-erbB1 
Epidermal growth factor receptor (EGFR) is one of four receptors in the pathway of 
epidermal growth factor transfer (HER, human epidermal growth factor receptor). It is a 
transmembrane glycoprotein consisting of 1186 amino acid residues. The gene encoding 
ErbB1 is located on chromosome 7 at p12.3-12.1. The emergence of mutation in this region 
leads to the appearance of mutated forms of EGFR. Three variants of these forms have been 
identified: I, II, III, with the mutation variant III (ΔEGFR) being most common. It involves 
the loss of the ligand binding site and leads to permanent spontaneous activation of the 
tyrosine kinase domain (Wojtukiewicz, 2010). 
The EGFR has three domains: extracellular, transmembrane and intracellular. The 
extracellular domain contains relatively high levels of cysteine residue. It is a site of mitogen 
activator binding (ligands ErbB1) ex. epidermal growth factor (EGF), tumor necrosis factor α 
(TNF α), and heparin binding EGF - (HB-EGF). After the ligand attaches to the EGFR there is 
a change in the conformational isomerism of the receptor particle and dimerization takes 
place. This interaction allows for the greatest utilization of the characteristics of various 
combining receptors (Wojtukiewicz, 2010). 
3. HER1/EGFR in gastric cancer 
Experiments using monoclonal antibodies against c-erbB1 have been carried out during the 
treatment of different tumors. Among others, tumor fighting properties of the monoclonal 
human-mouse chimera antibody have been used to neutralize cancer cells in the large 
intestine both in vitro and in vivo. The antibody, in the second phase of the experiment, has 
been adapted for patients with head, neck and lung tumors (Ghaderi, 2002). 
Meta-analysis showed the expression of c-erbB1 in gastric cancer in the range from 7.1% to 
as high as 80.0%. Positive correlation has been shown between the expression of this 
receptor and the diameter of the tumor, local invasion of the tumor and the spread of cancer 
cells to surrounding lymph nodes. Additionally, a relationship has been discovered between 
the stage of the tumor and the expression of c-erbB1. These results suggest c-erbB1 
www.intechopen.com
 
Human Epidermal Growth Factor Receptor Family (HER) in Gastric Cancer 
 
143 
involvement in the progression of gastric cancer in patients from Iran and can be considered 
to be a prognosticating factor in these tumors. Similarly, high expression of c-erbB1 and its 
positive correlation with those prognosticating factors can become useful tools for 
diagnosing and prognosis in gastric patients from Iran. As a result it has been suggested that 
the expression of this receptor should be monitored as part of routine patient screening 
(Ghaderi, 2002). 
4. c-erbB2, HER2/neu 
HER2/neu is a proto-oncogene encoding transmembrane tyrosine kinase with a mass of 185 
kDa. c-erbB-2 is encoded by a gene located on chromosome 17 (Ghaderi, 2002). Located on 
the cell membrane it binds with its extracellular growth factor ligands to HER-2 which leads 
to dimer formation with another HER-2 molecule or with HER-1, HER-3 or HER-4. 
Dimerization causes phosphorylation of tyrosine residue in the cytoplasmic domain of the 
receptor and a further activation of the intracellular transfer pathway, which regulates 
various biological reactions, including cell proliferation, differentiation, movement and 
survival. High expression of c-erbB-2 has been described in various types of tumors such as 
breast cancer, ovarian cancer, lung cancer, salivary gland cancer, cancer of the large 
intestine, prostate cancer and pancreatic cancer. It has also been suggested that this protein 
is an indicator of an unfavorable outcome ( Satiroglu- Tufan, 2006). 
ErbB2 does not have its own ligands and plays the role of a co-activator in relation to the 
other proteins of the ERBB family. Its basic signaling results from the ability to react with 
other ERBB receptors. The receptor can undergo stabilization as well as transactivation 
through the ligands specific to ERBB1 and ERBB3, which allows ERBB2 to take part in signal 
transfer. Heterodimers created by ERBB2 are considered to be particularly active (Citki, 
2003; Lee, 2001). 
Attachment of various ligands to the extracellular domain initiates the cascading of signal 
transduction. The ligand attaching to the EGFR induces homodimerization and 
heterodimerization with other types of HER proteins. HER2 does not attach to any known 
ligand but it is a preferred partner of heterodimerization for other members of the HER family. 
The HER2 gene, located adjacent to the topoisomerase IIa, is related to the oncogene v-erbB of 
the avian erythroblastosis virus. In tumors HER2 behaves like an oncogene, mainly because 
high level of gene amplification induces over-expression of the protein on the cell membrane 
and which then acquires characteristics typical to atypical cells (Gravalos, 2008). 
In normal cell signal transduction Her2 plays a role of a growth factor and is connected with 
the regulation of cell growth, survival and differentiation. Its downstream signaling can be 
activated by point mutations, gene amplification or gene over-expression. There exists a 
hypothesis that high ERBB2 expression aids spontaneous dimerization which contributes to 
ERBB2 activation and downstream signaling (Arrington, 2009). 
Amplification of the ERBB2 gene and/or the over-expression of its protein have been 
discovered in 20-30% of breast cancers. Over-expression of HER2, along with negative 
estrogen reception and early metastasis of these cancers, is treated as an independent factor 
predicting survivability and recurrence of the disease (Arrington, 2009). 
5. HER2 in gastric cancer 
HER2 expression in gastric cancer was described for the first time in 1986 (Gravalos, 2008). 
In breast tumors ERBB2 functions as an oncogene, with gene amplification and protein over-
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expression in the cell membrane. Not only is gene amplification an indicator of unfavorable 
prognosis it is also a predictive marker for therapies using the monoclonal antibody 
trastuzumab on patients with breast cancer with metastases. Amplification of ERBB2 has 
been found not only in breast cancers but in other malignant tumors such ovarian cancer, 
lung cancer, cancer of the large intestine and gastric cancer. With the use of 
immunohistochemistry, in gastric cancer the expression of ERBB2 has been shown in 5.2- 
22.6% of cases, while the percentage of ERBB2 amplification with the use of fluorescent in 
situ hybridization (FISH) was within the range of 3.8-12.2%. However, clinical significance 
of ERBB2 amplification/overexpression in gastric cancer patients is still unclear (Barros-
Silva, 2009). 
An anomaly most commonly found in tumors is gene amplification with an increase of 
HER2 protein expression. In people with gastric cancer HER2 over-expression/amplification 
is detected in 15-59% of advanced tumors. In gastric cancer the up-regulation of HER2 
expression can control the cell cycle, cell movement and invasion through several 
intracellular paths. HER2 signaling plays a fundamental role in the development, 
progression and metastasis of gastric cancer (Lee, 2010). 
When the HER2 signal spreads from the cell surface to the intracellular effectors it requires a 
signal transducer and activates Grb2 (growth factor receptor- bound 2). It is thought that 
Grb2, which facilitates HER2 signaling, plays a fundamental role in the development of 
breast cancer, its progression and metastasis. Janes et al. (1994) have shown that in breast 
cancer cells HER2 over-expression was connected with the Grb2-SOS1 complex, which 
activated the Raf/MEK/MAPK pathway through Ras. However, the role of Grb2 and its 
connection to HER2 were seldom described in gastric cancer. Yu et al. (2009) have shown 
that Grb2 overexpression in the main mass of the tumor as well as in metastasis occurs late 
in the process of gastric cancer development. Overexpression of Grb2, however, was 
connected with unfavorable prognosis for these patients. Researchers have also shown a 
significant correlation between Grb2 and HER2 in stomach tumors (Yu, 2009). 
Bao et al. (2010) utilized RNA interference in gastric cancer from SGC-7901 and MNK-45 
cultures to halt the activity of the HER2 oncogene. Through this work they have shown that 
HER2 is not only closely connected to tumor growth but also to its invasiveness. Even as 
Sarna-HER2 stopped the growth of gastric cancer cells, HER2 reduced the migration and 
invasiveness of cancer cells. By comparing the HER2- knockdown group with the control 
group the researchers discovered the presence of several markers of metastasis: COL1A1, 
ACTA2, E- katherine, MMP-2 and MMP-9. The knockdown of HER2 was accompanied by 
significant deregulation of MMP-1, despite unchanged levels of MMP-2 and MMP-9. They 
also demonstrated that HER2 can regulate MMP-1 expression at the transcription level. 
HER2 does not increase transcription activity through Myc, SRY, CREB or NF-κB 
attachment sites. This could be caused by downstream particles that have not been detected 
in bioinformatic analysis and which have the ability to attach to the MMP-1 promoter region 
and to regulate its transcription activity. Another interesting phenomenon was the fact that 
when MMP-1 was reduced the invasiveness of cells was nearly completely blocked. 
However, transcription of the MMP-1 expressing vector into shRNA-HER2 cells, which 
displayed a low ability for metastasis, resulted in only a partial restoration of the 
invasiveness of these cells. This data shows that MMP-1 is a downstream effector of HER2 
and that HER2 can have an influence on other particles connected to metastasis, with the 
exception of MMP-1 (Bao, 2010). 
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6. HER3 
The ERBB3 encoding gene is located on the 12 chromosome at q13. The proteins encoded by 
it show a low activity of tyrosine kinase. In comparison to ERBB2 and ERBB4, ERBB3 
displays a much lower homologation of the endothelial and cytoplast domains with the 
ERBB1 receptor, (Kraus, 1989; Lebeau, 2001). In all probability the ERBB3 by itself does not 
function as an oncogene, but increase of its expression can strengthen the oncogenic effect 
caused by the over expression of the ERBB2 receptor (Alimandii, 1995). 
7. HER3 in gastric cancer 
The expression of the HER3 protein is very often observed in advanced gastric tumors. It 
has been shown that HER3 expression is connected with gastric cancer progression and 
prognoses, while the HER1 or HER2 expression did not show a similar relationship. In the 
conducted in vitro experiments, HER3 blocking caused the decrease of the downstream 
signals and the death of tumor cells. It would seem that HER3 could be potentially useful in 
clinical treatment of cancer patients, especially those with stomach tumors. HER3 is 
associated with the signals mediated from HER1 or HER2, and it may be also associated 
with the resistance to anti-HER1 or anti-HER2 therapies. High expression of the HER3 
protein could be an indicator of an unfavorable prognosis for gastric cancer patients. 
Positive staining has been observed more often in advanced tumors with high malignancy 
when compared to early stage cancers, which can point to the involvement of this protein in 
the progression process of the disease. Co-expression of HER3 and HER2 has not been 
connected to gastric cancer prediction. The creation of a heterodimer of HER3/HER1 has 
been observed in gastric cancer cells. What is more, a relationship between the expression of 
HER3 and HER1 proteins has been observed. The expression of HER1 has been accepted as 
a prognosis indicator for patients with gastric cancer. The expression of HER3 protein had a 
stronger correlation with remote metastases and the survival time of gastric cancer patients 
then HER1 expression. The role of the HER4 protein expression in gastric cancer has not 
been determined. A positive immunohistochemical reaction to this protein has been equally 
often observed in early stage and in advanced gastric cancer. A recent study of gastric 
cancer cells show that the GER family kinases were targets of amplified fibroblast growth 
factor receptor 2, and the inhibition of HER3 which resulted in the loss of cell proliferation 
initiated by the fibroblast growth factor receptor 2. For this reason, therapies involving 
blocking of HER3 can become part of the new strategy in gastric cancer treatment, along 
with therapies using anti-HER1 and anti-HER2 treatments (Hayashi, 2008). 
Kabayashi et al. (2003) demonstrated that activation of phosphoinositide-3-kinase 
(P13K)/Akt triggered by phosphorylation of HER3 was important for dedifferentiatiated 
phenotypes of gastric cancer cell cultures. They also showed that HER3 signal pathway 
contributed to the development of dedifferentiated carcinomas by promoting motility and 
invasion of adenocarcinoma cells. This evidence supports the possible involvement of HER3 
in the dedifferentiation process of gastric cancer. 
8. HER4  
The gene encoding ERBB4 is located on chromosome 2 at q33.3-34 (Zimonjic, 1995). This 
gene is activated after combining with a neuroregulator, betacellulin and heparin-binding 
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EGF-like growth factor. Its activation leads to cell proliferation, chemotaxis or differentiation 
through the utilization of particular signal transferring proteins like P13K kinase and Shc 
(Carpentre, 2003). Even though the ERBB4 structure and function is similar to other 
members of the ERBB family it is still unclear what role, general or specific, ERBB4 plays in 
human tumor development. Protooncogenes, including EGFR and ERBB2, are most often 
evaluated in the light of mutation presence in tumors (Lynch, 2004; Peaz, 2004; Pao, 2004; 
Stephens, 2004; Shigama, 2005). For this reason it can be assumed that ERBB4 as a 
protooncogene is also subject to mutation in human tumors (Soung, 2006).  
Tvorogov et al (2009) has shown that 2 of 10 mutations destroy the catalytic activity of 
ERBB4 tyrosine kinase. However, despite losing tyrosine kinase activity, two mutated 
receptors were still able to form a "working" heterodimer with ERBB2 and to activate 
mitogen-actived protein kinase Erk and phosphoinositide 3-kinase/Akt pathway. The 
mutant receptors were able to activate Erk and phosphoinositide 3-kinase/Akt signaling 
pathway to a similar extent as the wild-type ERBB4. ERBB4 kinase activity was required for 
NRG-induced activation of the signal transducer and activator of transcription 5 (STAT5), 
resulting in failure of ERBB4 mutants to activate STAT5 (Tvorogov, 2009). Whereas Erk and 
phosphoinositide 3-kinase/Akt pathway have been implicated in the survival and 
proliferation of cancer cells, the role of STAT5 signaling in cancer is not yet fully 
understood, however increased STAT5 signaling has been associated with transformation. 
(Yu, 2004). 
9. HER4 in gastric cancer 
The role of ERBB4 in the process of carcinogenesis has not been completely defined. YH Soung 
et al. (2006) described ERBB4 kinase domain mutation in gastric, breast, lung and large 
intestine tumors. It is the first report describing mutation of the ERBB4 kinase domain in 
human tumors. The location of the mutation in the kinase domain, a location very important 
for functioning, can suggest that the discovery of ERBB4 mutation could be a change in 
function. (Soung, 2006). Stephens et al. (2005) found ERBB4 mutation in 1 of 25 studied breast 
tumors and it was found outside the kinase domain. Soung et al. (2006) has shown a 
convergence in the presence of ERBB4 and K-RAS mutations in gastric cancer, which can occur 
and could play a role in the process of pathogenesis of gastric cancer. These observations are 
different from previous observations where the K-RAS mutation in patients with lung cancer 
was not connected to neither EGFR nor ERBB2 mutations (Kosaka, 2004). The presence of 
ERBB4 mutation in commonly appearing human tumors, can act as a green light to initiate 
research into introduction of therapies aimed at eliminating mutated ERBB4.  
HER4 gene expression was higher in cancerous tissue in comparison to healthy tissue of a 
gastric tumor (Kataoka , 2008). 
10. HER2 amplification 
The amplification of the oncogene HER2 is an important biomarker in identification of 
patients who could react to HER2 therapy using the humanized monoclonal antibody 
transtuzumab (herceptin). Fluorescence in situ hybridization (FISH) or chromogenic in situ 
hybridization (CISH) can be used to assess weather tissue samples contain gene 
amplification. The FISH method is currently considered to be the "gold standard” in HER2 
amplification detection. This method has a high sensitivity (96.5%) and specificity (100%) 
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(Pauletti, 1996). An additional advantage of this method is that it can be used on small 
samples and cuttings preserved in formaldehyde or paraffin. FISH facilitates the direct 
display of gene amplification in the cell nucleus and enables gene and chromosome count 
on a cell-by-cell basis (Park, 2006). CISH is an attractive alternative to FISH. Tissue 
preparation and the process of sample hybridization are the same for both methods. These 
techniques differ in the method of detection which in CISH involves the initiation of a 
reaction with peroxidase which can be seen with the help of an optical microscope and that 
allows for an easy assessment of tissues and amplification products. Additionally, CISH 
allows the creation of a permanent record and is much cheaper than FISH. Since CISH is a 
relatively new method, the comparison between CISH and FISH is still being made in the 
clinical setting (Park, 2006). 
Wolf- Yadlin et al. (2006) made an attempt at explaining different effects of HER2 
amplification in carcinomas with different growth patterns. These researches suggested that 
HER2 overexpression causes an increase in cell migration but has a minimal effect on 
proliferation of cells being stimulated by the epidermal growth factor (EGF) or heregulin. 
For this reason HER2 amplification can increase cell migration in expanding tumors, while 
infiltrative carcinomas, which posses high invasive potential, do not gain additional 
advantages with HER2 amplification.  
Many researchers have shown that HER2 overexpression can be used as a prognostic factor 
for gastric cancer patients. The multi-variative analysis study performed by Brien et al. 
(1998) showed that the pathological stage and HER2 gene amplification are independent 
prognostic factors for survivability. Allgayer et al. (2000) confirmed the importance of HER2 
status as a prognostic factor in a prospective study of gastric cancer. They have 
demonstrated a significant association between the level of HER2 expression and shorter 
recovery and overall survival. 
11. Therapies using antibodies against the her family members 
11.1 Trastuzumab (herceptin)  
Trastuzumab (herceptin) is a recombined humanized monoclonal antibody anti-HER2mAb 
(rhuMAb HER2) with particle mass of 145531.5 g/mol. It was engineered from a cloned 
human IgG, with structure and antigen-binding residues of a potent murine mAb 4D5. 
Exact mechanics of how it behaves are not known, however it has been speculated that it 
plays a role in blocking the division of the HER2 receptor and dimerization; impedes the 
intracellular transference path P13K; has an anti-angiogenic effect by modulating the effects 
of pro and anti-angiogenic factors; or arresting cell proliferation in the G1 phase (Baselga, 
2009;Valabrega, 2007; Hayashi, 2008). 
Usually tastuzumab is well tolerated. When administered during therapy as the only 
medication side effects such as bone marrow suppression, nausea and vomiting or baldness 
are seldom observed (Hudis, 2007). However, trastuzumab therapy is connected with an 
increased risk of cardiotoxicity. This heart disorder is the most part reversible after 
discontinuation of the drug (Okines, 2010). 
It has been shown that in patients with HER2 positive breast cancer, herceptin treatment 
does extend survival time. Among breast cancer patients with metastases, high HER2 
expression and presence of amplification signified better effectiveness of trastuzumab 
therapy (Slamon, 2001).  
HER2 status is usually determined by immunohistochemistry (IHC) and/or in situ 
hybridization. In IHC the four-tiered scoring system described originally for the Food and 
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Drug Administration (FDA), the HerceptTest, has been approved. Samples scored as 0 and 
1+ are negative, 2+ as equivocal and 3+ as positive. However, the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines require in-
house validation of 1+ and 3+ samples with ISH before a certified laboratory can confine 
ISH retesting to 2+ samples (Batran, 2008). Recently, a modification of the HercepTest 
scoring system for gastric carcinomas was proposed (Table 1). 
 
Intensity 
score 
Staining pattern HER2 
expression surgical specimen biopsy specimen 
0 
no reactivity or membranous 
reactivity in <10% of tumor cells
no reactivity or membranous 
reactivity in any tumor cell
negative 
+1 
faint ⁄ barely perceptible 
membranous reactivity in 
≥10% of tumor cells; cells are 
reactive only in part of their 
membrane
tumor cell clusters with faint ⁄ 
barely perceptible membranous 
reactivity, regardless of percentage 
of tumor cells stained 
negative 
+2 
weak-to-moderate complete, 
basolateral or lateral 
membranous reactivity in 
≥10% of tumor cells 
tumor cell clusters with weak-to-
moderate complete, basolateral or 
lateral membranous reactivity, 
regardless of percentage of tumor 
cells stained
equivocal 
+3 
strong complete, basolateral or 
lateral membranous reactivity 
in ≥10% of tumor cells 
tumor cell clusters with strong 
complete, basolateral or lateral 
membranous reactivity, regardless 
of percentage of tumor cells stained 
positive 
Table 1. Recommended scoring system to evaluate immunohistochemistry staining patterns 
in patients with advanced gastric cancer. (Yoon, 2011). 
 
 
Fig. 1. HER2 testing algorithm in metastatic gastric and esophagogastric junction cancers. 
FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry (Yoon, 2011). 
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11.2 Cetuximab (anti-epidermal growth factor receptor monoclonal antibody)  
Cetuximab is a class IgG1 monoclonal antibody designed to bind with the epidermal growth 
factor receptor (GFR) (Martinelli, 2009). Cetuximab binds to the extracellular domain of the 
EGFR in its non-active configuration and competes to bind with the receptor through 
sealing the ligand binding site. This interaction of the antibody and the receptor prevents 
dimerization of the receptor and so blocks the tyrosine kinase activation dependant on the 
EGFR ligand. Additionally cetuximab induces EGFR internalization, downregulation and 
degradation. By provoking an anti-cancer response dependant on the immune system, 
cetuximab represses the proliferation of cancer cells (stops the G1 phase), the production of 
vascular endothelial growth factor (VEGF), tumor dependant angiogenesis and the invasion 
of cancer cells (Ciardiello, 2008; Lordick, 2010). 
The monoclonal antibody cetuximab has demonstrated antitumor efficacy both as a 
monotherapy and when combined with chemotherapy. (Lenz, 2006; Van Custen, 2007). 
Importantly, cetuximab treatment partially indicates that EGFR may improve resistance to 
irinotecan-based chemotherapy in a group of patients (Cuninghtam, 2004). Previous studies 
also reported that the EGFR TKI gefitinib worked well in combination with topo I inhibitors 
and platinum agents (Nagashima, 2006; Braun, 2005; Stewart, 2004; Van Schaeybroech, 2005). 
Pinto et al. (2009) published the results of the II phase of a study concerned with the 
treatment of patients with advanced gastric cancer with the drug combination: cetuximab 
and cisplatin. The response to this combination of drugs, observed at 41%, was higher than 
treatment with cisplatin or docetaxel alone. These researches have also shown that the entire 
progression rate was approximately eight months and was longer than during treatment 
with irinotecan or %- fluorouracil. Similar results were obtained by Lordick et al. (2010), 
with an average disease progression rate of 7.6 months. A slightly shorter disease 
progression time (about 5.5 months) and a response to treatment with cetuximab at 50% 
were observed by Han et al. (2009) in their research.  
11.3 Lapatinib  
Lapatinib is a potent ATP - a competitive inhibitor that simultaneously inhibits both EGFR 
and HER2. In cell-free biochemical kinase assays, lapatinib inhibits the recombinant EGFR 
and HER2 tyrosine kinase by 50% at concentrations of 10.8 and 9.3 nmol/L, respectively. In 
cell-based assays, lapatinib inhibits the growth of HER2-overexpressing BT474 breast cancer 
cells at comparably low concentrations of 100 nmol/L (Konecny, 2006).  
Lapatinib showed significant results when combined with trastuzumab in HER2- amplified 
gastric cancer cells. The combination of lapatinib and trastuzumab induces nearly complete 
tumor regression in all of the mice that have been treated. Those effects were much more 
pronounced than either lapatinib or trastuzumab alone (Wainberg, 2010). Although results 
of Wainberg et al. (2010) were only preliminary, they support the ongoing investigation of 
lapatinib in gastric cancer as well as its possible combination with trastuzumab in HER2- 
amplified disease. The addition of anti-HER2 therapy to standard chemotherapy could have 
direct clinical benefit and makes the investigation of additional anti-HER2 therapies in 
upper gastrointestinal cancers, very desirable (Wainberg, 2010). 
HER2 amplification is an important prognosis factor for the growth inhibitory activity of 
lapatinib in gastric cancer. Kim et al. (2008) has shown that lapatinib inhibits the 
phosphorylation of EGFR and HER2, and through this also impedes signal transfer from 
Akt and Erk in the gastric cancer cells sensitive to lapatinib. Lapatinib halted the G1 phase 
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of the cell cycle in cell cultures SNU-216, NCI-N87 and SNU-484, which displayed a growth 
inhibitory effect at higher concentrations. Furthermore, cMyc reduction and p27kip1 
induction were also observed after lapatinib treatment. Conversely, the induction of 
apoptosis by lapatinib is linked to the inhibition of the Akt pathway, rather than the Erk 
pathway (Kim, 2008). Lapatinib blocks Erk phosphorylation through the stimulation of the 
IGF-1 ligand. However, the inhibitory effects for IGF-1- stimulated phosphorylation of the 
IGF-1 receptor were not seen in SNU-484. It could be that lapatinib inhibits the downstream 
signaling of the phosphorylated IGF-1 receptor via EGFR, considering that it is a complex 
between the IGF-1 receptor and EGFR which activates the Erk pathway (Kim, 2008). 
Lapatinib, in combination with 5-FU, is currently used as the prodrug capecitabine in 
treating patients with breast cancers with HER2 expression in a clinical investigation of solid 
tumors (Geyer, 2006). It has been shown that lapatinib exhibits a high anticancer 
effectiveness in cells with high EGFR or HER2 expression (Rusnak, 2007; Konecny, 2006). 
Overexpression and/or amplification of HER2 in patients with breast cancer have been 
determined to be important prognostic factors in treating with lapatinib (Konecny, 2006). 
11.4 Gefitinib 
Gefitinib is an orally active, quinazoline tyrosine kinase inhibitor, selective for EGFR. Its 
anticancer effectiveness has been shown in lung cancer treatment. Somatic mutations within 
the ATP- binding pocket of the tyrosine kinase domain of the EGFR, including small in-
frame deletions and missense substitutions, are present in lung adenocarcinomas and confer 
responsiveness to gefitinib in lung cancer patients (Lynch, 2004; Paez, 2004). Yokoyama et al. 
(2006), have shown for the first time that cell cultures (GLM-1, GLM-2 i GLM-4, NCI-N87) of 
gastric cancers were more sensitive to gefitinib than traztuzumab. Gefitinib induced 
apoptosis in cells demonstrating HER2 overexpression, something that has not been 
observed in commonly used gastric cancer cell cultures without HER2 expression.  
It still seems unclear why gefitinib, an EGFR inhibitor, displays anticancer properties with 
gastric cancer cells that are HER2 positive but not those that are EGFR positive. Anido et al. 
(2003) have put forward a hypothesis that gefitinib prevents the formation of HER2/HER3 
heterodimers by taking part in the sequestration of HER2 and HER3 with inactive 
(nonphosphorylated) EGFR/HER2 and EGFR/HER3 heterodimers. Yokoyama et al. (2006) 
has shown that gefitinib can selectively arrest the phosphorylation of Akt only in cells with 
HER2 overexpression, although cells with low HER2 expression also displayed constitutive 
activation of P13K/Akt pathway. This suggests that gefitinib can selectively block activated 
P13K/Akt pathways only because it is simply driven by HER2 overexpression along with 
relatively high expression of HER3, which permits the formation of the HER2/HER3 
heterodimer (Yokoyama, 2006). The other interesting discovery made by these researchers 
has been the claim that gastric cancer cell cultures with HER2 overexpression become 
resistant to gefitinib. Gefitinib resistant cells of the GLM-1R culture have displayed an 
increase of EGFR expression and a more differentiated morphology in comparison to 
parental cells of the GLM-1 culture. The Shs and Erk1/2, upstream and downstream 
signaling molecules of the MAPK pathway, were also upregulated in GLM-1R cells. 
Additionally, the inhibition of the phosphorylation of Akt in GLM-1 parental cells in 
response to gefitinib treatment was weakened when the path Ras/MAPK was highly 
stimulated by higher concentrations of EGF. These observations can suggest that the 
pathway EGFR-Ras-MAPK is really (but in moderation) activated in compensation for the 
blockage of the HER2-P13K-Akt pathway in GML-1R cells, which results in persistent 
growth when gefitinib is present and the build up of resistance (Yokoyama, 2006). 
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12. Immunohistochemical evaluation expression of her2 and her1/egfr 
Many investigators subsequently evaluated HER2 status in gastric cancer cells by IHC 
(immunohistochemistry). The frequency of HER2 overexpression was varied widely from 8 
to 31 %. The consensus of almost all reports is that the majority of positive cases are the 
intestinal type histologically. Methods of IHC which evaluate for HER2 status in gastric 
cancer have not been standardized and that is a wide range in the frequency of 
overexpression, furthermore, there have been few reports claiming to have demonstrated 
HER2 gene amplification in gastric cancer (Sato, 1997; Takehana, 2002). 
There are conflicting results in studies of HER2 with regard to its relationship to prognosis 
in gastric cancer patients. Some studies have reported that HER2 overexpression is a poor 
prognostic factor for gastric cancer (Uchino, 1993; Chariyalertsah, 1994; Mizutani, 1993). DI 
Park 2006 demonstrated that HER2 is an prognostic parameter in gastric cancer. Similar 
finding demonstrated Yonemura et al. (1991, 1991). They showed that immunoreactivity to 
HER2 can be an independent prognostic value in gastric cancer. Mizutani et al. (1993) 
reported significantly poorer prognoses for patients suffering from early gastric cancer who 
were HER2 positive in IHC. However, other studies have failed to fund any association with 
prognosis whatsoever (Hilton, 1992; Kołodziejczyk, 1994; Tateishi, 1992; Sasano, 1993). Orita 
et al. (1997) elucidated prognostic significance of the expression of c-erbB-2 oncogene in 
gastric cancer patients. They found out that c-erbB-2 protein expression was associated with 
considerably shorter postoperative survival time. In patients with positive and negative c-
erbB-2 expression, a 5-year survival reached 29% and 47%, respectively. Similar results have 
been reported by some other authors (Tsugawa, 1998; Nakajima, 1999; Pinto-de-Sousa, 
2002). These data suggest that c-erbB-2 expression can be a prognostic factor for gastric 
cancer patients. However, according to other studies, c-erbB-2 does not exert a significant 
effect on the overall survival time of gastric cancer patients (Gurel, 1999; Polakowski, 1999). 
The first preliminary data concerning the level of EGFR in the gastric wall were described 
by Yasiu et al. (1988), indicating an increase in the level of EGFR in neoplastic tissue 
compared to normal mucus. Similar observations have been reported by other authors 
(Kopp, 2002; Coyle, 1999). Kopp et al. (2002) suggested that in case of chronic inflammation 
or tissue damage the physiological effect of the ligand for the EGF-receptor pathway, 
associated with the regulation of regeneration and healing in the gastric mucus, may 
additionally stimulate the process of neoplastic transformation in the gastric mucus and 
tumor progression. We observed EGFR expression in 50% of the evaluated cases of gastric 
cancer. High expression was observed mainly in the intestinal type and poorly 
differentiated cancers, as well as in those infiltrating the whole gastric wall or at least into 
the muscular layer. However, we found no statistical significance. As reported by Gamboza-
Dominguez et al. (2004), lack or low expression of EGFR protein was significantly correlated 
with prolonged postoperative survival time, as compared to the moderate and strong 
expression.  
13. Conclusion 
Signaling through the HER pathway plays a fundamental role in the regulation of cell 
growth, proliferation, migration and survival of neoplastic cells. Moreover, HER signaling 
can be activated as a response to different therapies used to treat cancer, like chemotherapy 
or radiation therapy, and can lead to cell and tissue damage. Elevated signal transfer activity 
can be connected to an increased risk of tumor development and malignancy. Positive 
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correlation has been shown between the expression of these receptors and the local invasion 
of the tumor, lymph nodes metastases and stage of gastric cancer. .Overexpression of these 
factors may be a prognosticating factor in these tumors. As a result it has been suggested 
that the expression of HER family receptors should be monitored as part of routine patient 
screening. It was suggested, that blocking of the action of GER family receptors can be used 
in the treatment of gastric cancer. These agents, combined with chemiotherapy and other 
targeted can be used in the future as a oncological therapy. 
14. Referenses 
Ghaderi, A; Vasei, M; Maleck-Hosseini, SA; Gharesi- Fard, B; Khodami, M; Dorouchi, M; 
Modjtahedi, H. (2002).    The expression of c-erbB-1 and cerbB-2 in Iranian patients 
with gastric carcinoma. Pathology Oncology Research, Vol.8, No.4, pp252-256. 
Zhau, HE; Wan, DS; Zhou, J; Miller, GJ; von Eschenbach, AC. (1992). Expression of c-erbB-
2/neu proto- oncogene in human prostate cancer tissues and cell lines. Mol 
Carcinog, 5, pp320-327. 
Liang, K; Ang, KK; Milas, L; Hunter, N; Fan, Z. (2003). The epidermal growth factor receptor 
mediates radioresistance. Int J Radiat Oncol Biol Phys, 57, pp246-245 
Iwamoto, R; Mekada, E. (2006). ErbB and HG-EGF signaling in heart development and 
function. Cell Struct Funct, 31, pp1-14. 
Walles, A. (1999). EGF receptor. Int J Biochem Cell Biol, 31, pp637. 
Wojtukiewicz, MZ; Sierko, E; Szambora, P. (2010). Patofizjologiczne podstawy terapii 
ukierunkowanej na zahamowanie funkcji receptora czynnika wzrostu naskórka 
(EGFR). Onkol Prak Klin, Vol.6, No.5, pp217-227. 
Satiroglu- Tufan, NL; Bir, F; Calli-Demirkan, N. (2006). Investigation of HER-2 codon 655 
single nucleotide polymorphism frequency and c-ErbB-2 protein expression 
alterations in gastric cancer patients. World J Gastroenterol, Vol.12, No.20, pp3283-
3287, ISSN 1007- 9327. 
Citki, A; Kochuperakkal, BS; Yarden, Y. (2003). The deaf and dumb: the biology of ErbB-2 
and ErbB-3. Exp Cell Res, 284, pp54. 
Lee, H; Akita, RW; Sliwkowski, MX; Maihle, NJ. (2001). A naturally occurring secreted 
human ErbB-2, ErbB-3, and ErbB- 4. Cancer Res, pp4467. 
Gravalos, C; Jimeno, A. (2008). HER2 in gastric cancer: a new prognostic factor and a novel 
therapeutic target. Annals of Oncology, 19, pp1523-1529. 
Arrington, AK; Dahlerg PS; Davydova, J; Veckers, SM; Yamamoto, M. (2009). ERBB2 
suppression decreases cell growth via apoptosis in gastrointestinal 
adenocarcinomas. Surgery, 146, pp213-219. 
Barros-Silva, JD;Leitão, D; Afonso, L; Vieira, J; Dinis- Riberio, M; Fragoso, M; Bento, MJ; 
Santos, L; Ferreira, P; Rêgo, S; Brandão,C; Carneiro, F; Lopes, C; Schmitt, F; 
Teixeira, MR. (2009). Association of ERBB2 gene status with histopathological 
parameters and disease- specific survival in gastric carcinoma patients. British 
Journal of Cancer, 100, pp487-493. 
Lee, MS; Cha, EY; Thuong, PT; Kim, JY; Ahn, MS; Sul, JY. (2010). Down-regulation of human 
epidermal growth factor receptor 2/neu oncogene by corosolic acid induces cell 
cycle arrest and apoptosis in NCI-N87 human gastric cancer cells. Biol Pharm Bull, 
33, pp931-937. 
Janes, PW; Daly, RJ; DeFazio, A; Sutherland, RL. (1994). Activation of the Ras signaling 
pathway in human breast cancer overexpressing erbB-2. Oncogene, 9, pp3601-3608. 
www.intechopen.com
 
Human Epidermal Growth Factor Receptor Family (HER) in Gastric Cancer 
 
153 
Yu, GZ; Chen, Y; Wang, JJ. (2009). Overexpression of Grb2/HER2 signaling in Chinese 
gastric cancer: their relationship with clinicopathological parameters and 
prognostic significance. J Cancer Res Clin Oncol, 135, pp1331-1339. 
Bao, W; Fu, HJ; Jia, LT; Zhang, Y; Li, W; Jin, BQ; Yao, LB; Chen, SY; Yang, AG. (2010). HER2- 
mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. 
Archives of Biochemistry and Biophysics, 499, pp49-55. 
Kraus, MH; Issing, W; Miki, T; Popescu, NC; Aaronson, SA (1989). Isolation and 
characterisation of c-erbB3, a third member of the erbB-epidermal growth factor 
receptor family; evidence of overexpression in a subset of human mammary 
tumours. Proc Natl Acad Sci, USA, 86, pp9193- 9197.  
Lebeau, A; Deimling, D; Kaltz, C; Sendelhofert, A; Iff, A; Luthardt, B; Untch, M; Löhrs U. 
(2001). HER-2/neu analysis in archival tissue samples of human breast cancer: 
comparision of immunohistochemistry and fluorescence in situ hybridization. J 
Clin Oncol, 19, pp354- 363. 
Alimandii, M; Romano, A; Curia, MC, Muraro, R; Fedi, P; Aaronson, SA; Di Fiore, PP; 
Kraus, MH. (1995). Cooperative signaling of ERB-3 and ERB-2 in neoplastic 
transformation and human mammary carcinomas. Oncogene, 10, pp1813.  
Hayashi, M; Inokuchi, M; Takagi, Y; Yamada, H; Kojima, K; Kumagai, J; Kawano, T; 
Sugihara, K. (2008). High expression of HER3 is associated with decreased survival 
in gastric cancer. Clin Cancer Res, 14,pp7843-7849.  
Kabayashi, M; Iwamatsu, A; Shinohara-Kanda, A; Ihara, S; Fukui, Y. (2003). Activation of 
ErbB3-P13-kinase pathway is correlated with malignant phenotypes of 
adenocarcinomas. Oncogene, 22, pp1294-1301. 
Zimonjic, DB; Alimandii, M; Miki, T; Popescu, NC; Kraus, MH. (1995). Localization of the 
human HER4/ERBB-4 gene to chromosome 2. Oncogene, 10, pp1235- 1237.  
Carpentre, G. (2003). ErbB-4: mechanism of action and biology. Exp Cell Res, 284, p66-77. 
Lynch, TJ; Bell, DW; Sordella, R; Gurubhagavatula, S; Okimoto, RA; Brannigan, BW; Harris, 
PL; Haserlat, SM; Supko, JG; Haluska, FG; Louis, DN; Christiani, DC; Settleman, J; 
Haber, DA. (2004). Activating mutations in the epidermal growth factor receptor 
underlaying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 
350, pp2129- 39. 
Peaz, JG; Janne, PA, Lee, JC; Tracy, S; Greulich, H; Gabriel, S; Herman, P; Kaye, FJ; 
Lindeman, N; Boggon, TJ; Naoki, K; Sasaki, H; Fujii, A; Eck, MJ; Sellers, WR; 
Johnson, BE; Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with 
clinical response to gefitinib therapy. Science, 304,pp1497-500. 
Pao, W; Miller, V; ZAkowski, M; Doherty, J; Politi, K; Sarkaria, I; Singh, B; Heelan, R; Rusch, 
V; Fulton, L; Mardis, E; Kupfer, D; Wilson, R; Kris, M; Varmus, H. (2004). EGF 
receptor gene mutations are common on lung cancer from “never smokers” and are 
associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 
USA, 101, pp13306-13311. 
Stephens, P; Hunter, C; Bignell, G; Edkins, S; Davies, H; Teague, J; Stevens, C; O’Meara, S; 
Smith, R; Parker, A; Barthorpe, A; Blow, M; Brackenbury, L; Butler, A; Clarke, O; 
Cole, J; Dicks, E; Dike, A; Drozd, A; Edwards, K; Forbes, S; Foster, R; Gray, K; 
Greenman, C; Halliday, K; Hills, K; Kosmidou, V; Lugg, R; Menzies, A; Perry, J; 
Petty, R; Raine, K; Ratford, L; Stepherd, R; Small, A; Stephens, Y; Tofts, C; Varian, J; 
West, S; Widaa, S; Yates, A; Brassuer, S; Cooper, CS; Flanagan, AM; Knowles, M; 
Leung, SY; Louis, DN; Looijenga, LH; Malkowicz, B; Pierotti, MA; Teh, B; 
Chenevix-Trench, G; Weber, BL; Yuen, ST; Harris, G; Goldstraw, P; Nicholson, AG; 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
154 
Futreal, PA; Wooster, R; Stratton, MR. (2004). Lung cancer: intragenic ERBB2 kinase 
mutations in tumours. Nature, 431, pp525-526. 
Shigematsu, H; Takahashi, T; Nomura, M; Majmudar, K; Suzuki, M; Lee, H; Witsuba, II; 
Fong, KM; Toyooka, S; Shimizu, N; Fujisawa, T; Minna, JD; Gazdar, AF. (2005). 
Somatic mutations of the HER2 kinase domain in lung adenorarcinomas. Cancer 
Res, 65, pp1642-1646.  
Soung, YH; Lee, JW; Kim, SY; Wang, YP;Jo, KH; Moon, SW; Park, WS; Nam, SW; Lee, JY; 
Yoo, NJ; Lee, SH. (2006). Somatic mutations of the ERBB4 kinase domain in human 
cancers. Int J Cancer, 118, pp1426-1429. 
Tvorogov, D; Sundvall, M; Kurppa, K; Hollmén, M; Repo, S; Johnson, MS; Elenius, K. (2009). 
Somatic mutations of ErbB4- selective loss-of-function phenotype affecting signal 
transduction pathways in cancer. J Biol Chem, 284, pp5582-5591. 
Yu, H; Jove, R. (2004). The STATs of cancer--new molecular targets come of age. Nat Rev 
Cancer, 4, pp97-105. Stephens, P; Edkins, S; Davies, H; Greenman, C, Cox C; Hunter, 
C; Bignell, G; Teague, J; Smith, R; Stevens, C; O’Meara, S; Parker, A; Tarpey, P; 
Avis, T; Barthorpe, A; Brackenbury, L; Buck, G; Butler, A; Clements, J; Cole, J; 
Dicks, E; Edwards, K; Forbes, S; Gorton, m; Gray, K; Halliday, K; Harrison, R; Hills, 
K; Hinton, J; Jones, D; Kosmidou, V; Laman, R; Lugg, R; Menzies, A; Perry, J; Petty, 
R; Raine, K; Shepherd, R; Small, A; Solomon, H; Stephens, J; Tofts, C; Varian, J; 
Webb, A; West, S; Widaa, S; Yates, A; Brasseur, F; Cooper, CS; Flanagan, AM; 
Green, A; Knowles, M; Leung, SY; Looijenga, LH; Malkowicz, B; Pierotti, AM; Teh, 
B; Yuen, ST; Nicholson, AG; Lakhani, S; Easton, DF; Weber, BL; Stratton, MR; 
Futreal, PA; Wooster, R. (2005). A screen of the complete protein kinase gene family 
identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet, 
37, pp590-592. 
Kosaka, T; Yatabe, Y; Endoh, H; Kuwano, H; Takahashi, T; Mitsudomi, T. (2004). Mutations 
of the epidermal growth factor receptor gene in lung cancer: biological and clinical 
implications. Cancer Res, 64, pp8919-8923. 
Kataoka,H; John, T; Kasugasi, K; Okayama, N; Moriyama, A; Asai, K; Kato, T. (2008). 
Expression of mRNA for heregulin and its receptor, ErbB-3 and ErbB-4, in human 
upper gastrointestinal mucosa. Life Sci, 63, pp553-564. 
Pauletti, G; Godophin, W; Press, MF, Salomon, DJ. (1996). Detection and quantitation of 
HER-2/neu gene amplification in human breast cancer archival material using 
fluorescence in situ hybridization. Oncogene, 13, pp63-72. 
Park, DIL; Yun, JW.; Park, JH; Oh, SJ, Kim, HJ; Cho, YK; Sohn, CIL; Jeon, WK; Kim, BI; Yoo, 
CH; So, BH; Cho, EY; Chae, SW; Kim, EJ; Sohn, JH; Ryu, SH; Sepulveda, AR. (2006). 
HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig 
Dis Sci, 51, pp1371-1379. 
Wolf-Yadlin, A; Kumar, N; Zhang, Y; Hautaniemi, S; Zaman, M; Kim, HD; Grantcharova, V; 
Lauffenburger, DA; White, FM. (2006). Effects of HER2 overexpression on cell 
signaling networks governing proliferation and migration. Mol Syst Biol, 2,pp1-15. 
Brien, TP; Depowski, PL; Sheehan, CE; Ross, JS; McKenna, BJ. (1998). Prognostic factors in 
gastric cancer. Mod Pathol, 11, pp870-877. 
Allgayer, H; Babic, R; Gruetzner, KU; Tarabichi, A; Schiidberg, FW; Heiss, MM. (2000). c- 
erb-B2 is on independent prognostic relevance in gastric cancer and is associated 
with the expression of tumor- associated protease system. J Clin Oncol, 18, pp2201-
2209. 
Baselga, J; Swain, SM. (2009). Novel anticancer targets: revisting ERBB2 and discovering 
ERBB3. Nat Rev Cancer, 9, pp463-475. 
www.intechopen.com
 
Human Epidermal Growth Factor Receptor Family (HER) in Gastric Cancer 
 
155 
Valabrega, G; Montemurro, F; Aglitta, M. (2007). Transtuzumab:mechanism of action, 
resistance and future perspectives in HER2-overexpressing breast cancer. Ann 
Oncol, 18, pp977-984. 
Hudis, CA. (2007). Transtuzumab- mechanism of action and use in clinical practice. N Engl J 
Med, 357, pp39-51. 
Okines, AFC; Cunningham, D. (2010). Transtuzumab in gastric cancer. European Jurnal of 
Cancer, 46, pp1949-1959. 
Slamon, DJ; Leyland-Jones, B; Shak,S Fuchs, H; Paton, V; Bajamonde, A; Fleming, T; 
Eiermann, W; Wolter, J; Pegram, M; Baselga, J; Norton, L. (2001). Use of 
chemotherapy plus a monoclonal antibody against HER2. N Engl J Med, 344, pp783-
792. 
Batran, AL; Hartmann, JT; Probst, S; Schmalenberg, H; Hollerbach, S; Hofheinz, R; 
Rethwisch, V; Seipelt, G; Homann, N; Wilhelm, G; Schuch, G; Stoehlmacher, J; 
Derigs, HG; Hegewisch-Becker, S; Grossmann, J; Pauligk, C; Atmaca, A; 
Bokemeyer, C; Knuth, A; Jäger, E. (2008). Phase III trial in metastatic 
gastroesophagel adenocarcinoma with fluorouracil, leucovorin plus either 
oxaplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistiche Onkologie. J 
Clin Oncol, 26, pp1435-1442. 
Yoon, H; Kang, YK. (2011). Recommended scoring system to evaluate 
immunohistochemistry staining patterns in patients with advanced gastric cancer. 
Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. 
Clinical Investigation 1(1), pp87-95.  
Mortinelli, E; De Palma, R; Orditura, M; De Vita, F; Ciardiello, F. (2009). Anti-epidermal 
growth factor receptor monoclonal antobodies in cancer therapy. Clin Exp Immunol, 
158,pp1-9. 
Ciardiello, F; Tortora, G. (2008). EGFR antagonists in cancer treatment. N Ehngl J Med, 358, 
pp1160-1174. 
Lordick, F; Luber, B; Lorenzen, S; Hegewisch-Becker, S; Folprecht, G; Wöll, E; Decker, E; 
Endlicher, E; Röthling, N; Schuster, T;Keller, G; Fend, F; Peschel, C. (2010). 
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic 
gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistiche Onkologie 
(AIO). British Journal of Cancer, 102, pp500-505. 
Lenz, HJ; Van Custem, E; Khambata-Ford, S; Mayer, RJ; Gold, P; Stella P; Mirtsching, B; 
Cohn, AL; Pippas, AW; Azarnia, N; Tsuchihashi, Z; Mauro, DJ; Rowinsky, EK. 
(2006). Multicenter phase II and Translational study of cetuximab in metastatic 
colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J 
Clin Oncol, 24, pp4914-4921. 
Van Cutsem, E; Nowacki, MP; Lang, I; Cascinu, S; Shcheptin, I; Maurel, J; Rougier, P; 
Cunningham, D; Nippen, J; Kohne, C. (2007). Randomized phase III study of 
irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of 
patients with metastatic colorectalcancer (mCRC): the CRYSTAL trial. J Clin Oncol, 
25, abstract 4000. 
Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, 
M; Harstrick, A;  
Verslype, C; Chau, I, Van Cutsem, E. (2004). Cetuximab monotherapy and cetuximab plus 
irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351, 
pp337-345. 
Nagashima, S; Soda, H; Oka, M; Kitazaki, T; Shiozawa, K; Nakamura, Y; Takemura, M; 
Yabuuchi, H; Fukuda, M; Tsukamoto, K; Kohno, S. (2006). BCRP/ABCG2 levels 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
156 
account for the resistance to topoisomerase I inhibitors and reversal effects by 
gefitinib in non-small cell lung cancer. Cancer Chemiother Pharmacol, 58,pp594-600. 
Braun, AH; Stark, K; Dirsch, O; Hilger, RA; Seeber, S; Vanhoefer, U. (2005). The epidermal 
growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer 
cells to irinotecan. Anticancer Drungs, 16, pp1099-1108. 
Steward, CF; Leggas, M; Schuetz, JD; Panetta, JC; Cheshire, PJ; Peterson, J; Daw, N; Jenkins, 
JJ; Gilberson, R;  
Germain, GS; Harwood, Fc; Houghton, PJ. (2004). Gefitinib enhances the antitumor activity 
and oral bioavailability of irinotecan in mice. Cancer Res, 64, pp7491-7499. 
Van Schaeybroeck, S; Karaiskou-McCaul, A; Kelly, D; Longley, D; Galligan, L; Van Cutsem, 
E; Johnson, P. (2005). Epidermal growth factor receptor activity determines 
response of colorectal cancer cells to gefitinib alone and in combination with 
chemiotherapy. Clin Camcer Res, 11, pp7480-7489. 
Pinto, C; Di Fabio, F; Siena, S; Cascinu, S; Llimpe, FL; Ceccarelli, C; Mutri, V; Giannetta, L; 
Giaquinta, S; Funaioli, C; Berardi, R; Longobardi, C; Piana, E; Martoni, AA. (2007). 
Phase II study of cetuximab in combination with FOLFIRI in patients with 
untreated advanced gastric or gastroesophageal junction adenocarcinoma 
(FOLCETUX study). Ann Oncol, 18, pp510-517. 
Han, SW; Oh, DY; Im, SA; Lee, KW; Song, HS; Lee, NS; Lee, KH; Choi, IS; Lee, MH; Kim, 
MA; Kim, WH; Bang, YJ; Kim, TY. (2009). Phase II study and biomarker analisis of 
cetuximab combined with modifiedFOLFOX6in advanced gastric cancer. Br J 
Cancer, 100, pp298-304.  
Konecny, GE; Pegram, MD, Venkatesan, N; Finn, R; Yang, G; Rahmeh, M; Untch, M; 
Rusnak, DW; Spehar, G; Mullin, RJ; Keith, BR; Gilmer, TM; Berger, M; Podratz, KC; 
Slamon, DJ. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) 
against HER-2- overexpression and transtuzumab- treated brest cancer cells. Cancer 
Res, 66, pp1630-1639. 
Wainberg, ZA; Anghel, A; Desai, AJ; Ayala, R; Luo, T; Safran, B; Fejzo, MS; Hecht, JR; 
Slamon, DJ; Finn, RS. (2010). Lapatinib, a dual EGFR and HER2 kinase inhibitor, 
selectively inhibits HER2- amplified human gastic cancer cells and is synergistic 
with Trastuzumab in vitro and in vivo. Clin Cancer Res,16, pp1509-1519. 
Kim, JW.; Kim, HP; Im, SA; Kang, S; Hur, HS; Yoon, YK; Oh, DY; Kim, JH; Lee, DS.; Kim, 
TY; Bang, YJ. (2008). The growth inhibity effect of lapatinib, a dual inhibitor of 
EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters, 272, 
pp296-306. 
Geyer, CE; Forster, J; Lindquist, D; Chan, S; Romie, CG; Pienkowski, T; Jagiello- Gruszweld, 
A; Crown, J; Chan, A; Kauffman, B; Skarlos, D; Campone, M; Davidson, N; Berger, 
M; Oliva, C; Rubin, SD; Stein, S; Cameron, D. (2006). Lipatinib plus capecitabine for 
HER2-positive advanced breast cancer. N Engel J Med., 355, pp2733-2743. 
Rusnak, DW; Alligood, KJ; Mullin, RJ; Spahar, GM; Arenas-Elliott, C; Martin, AM; 
Degenhardt, Y; Rudolph, SK; Haws, TF; Hudson-Curtis, BL; Gilmer, TM. (2007). 
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) 
protein expression levels and response to lapatinib (Tykerb, GW572016) in an 
expanded panel of human normal and tumor cell lines. Cell Prolif, 40, pp580-594. 
Yokoyama, H; Ikehara, Y; Kodera, Y; Ikehara, S; Yatabe, Y; Mochizuki, Y; Koine, M; 
Fujiwara, M; Nakao, A; Tatematsu, M; Nakanishi, H. (2006). Molecular basis for 
sensitivity and acquired resistance to gefitinib in HER2-overexpressing human 
gastric cancer cell lines derived from liver metastasis. British J Cancer, 95, pp1504-
1513. 
www.intechopen.com
 
Human Epidermal Growth Factor Receptor Family (HER) in Gastric Cancer 
 
157 
Anido, J; Matar, P; Albanell, J; Guzman, M; Rojo, F; Arribas, J; Averbuch, S; Baselga, J. 
(2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 
heterodimers and prevents heregulin signaling in HER2-overexpressing breast 
cancer cells. Clin Cancer Res, 9, pp1274-1283. 
Sato, T; Abe, K; Kurose, A; Uesugi, N; Todokori, T; Sasaki, K. (1997). Ampification of the c- 
erbB-2 gene detected by FISH in gastric cancers. Pathol Int, 47, pp179-182. 
Takehana, T; Kunitomo, K; Kono, K; Kitahara, F; Iizuka, H; Matsumoto, Y; Fujino, AF; Ooi, 
A. (2002). Status of c-erbB-2 in gastric adenocarcinoma: a comparative study o 
immunohistochemistry, fluorescencje in situ hybrydyzation and enzyme-linked 
immunosorbent assai. Int J Cancer, 98, pp833-837. 
Uchino, S; Truda, H; Marayama, K; Kinoshita, T; Sasako, M; Saito, T; Kobayashi, M; 
Hirohashi, S. (1993). Overexpression of c-erb-B2 protein in gastric cancer. Its 
correlation with long term survival of patients. Cancer, 72, pp3179-3184. 
Chariyalertsak, S; Sugano, K; Ohkura, H; Mori, Y. (1994). Comparison of c-erb-B2 
oncoprotein expression in tissue and serum of patients with stomach cancer. Tumor 
Biol, 15, pp294-303. 
Mizutani, T; Onda, M; Tokunaga, A; Yamanaka, N; Sugisaki, Y. (1993). Relationship of c- 
erb- B2 protein expression and gene amplification to invasion and metastasis in 
human gastric cancer. Cancer, 72, pp2083-2038. 
Yonemura, Y; Ninomiya, I; Ohoyama S; Kimura, H; Yamaguhi, A; Fushida, S; Kosaka, T; 
Miwa, K; Miyazaki, I; Endou, Y; at al.(1991). Expression of c-erbB-2 oncoprotein in 
gastric carcinoma. Immunoractivity for c-erbB-2 protein is an indicator of poor 
short- term prognosis in patients with gastric carcinoma. Cancer, 67, pp2914-2918. 
Yonemura, Y; Ninomiya, I; Yamaguchi, A; Fushida, S; Kimura, H; Ohoyama, S; Miyazaki, I; 
Endou, Y; Tanaka, M; Sasaki, T. (1991). Evaluation expressionof immunoractivity 
for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer 
Res,51;pp1034-1038. 
Hilton, DA; West, KP. (1992). c-erb-B2 oncogene product expression and prognosis in gastric 
carcinoma. J Clin Pathol, 45, pp454-456. 
Kolodziejczyk, P; Yao, T; Oya, M; Nakamura, S; Utsunomiya, T; Ishikawa, T; Tsuneyoshi, M. 
(1994). Long- term follow-up study of patients with gastric adenomas with 
malignant transformation. An immunohistochemical and histochemical analysis. 
Cancer, 74, pp2896-2907. 
Tateishi, M; Toda, T; Minamisono, Y; Nagasaki, S. (1992). Clinicopathological significance of 
c-erb-B2 protein expression in human gastric carcinoma. J SurgOncol, 49, pp209-212. 
Sasano, H; Date, F; Imatani, A; Asaki, S; Nagura, H. (1993). Double immunostaining for c- 
ereb-B2 and p53 in human stomach cancer cells. Hum Pathol, 24, pp584-589. 
Orita, H; Maehara, Y; Emi, Y; Kakeji, Y; Baba, H; Korenaga, D; Sugimachi, K. (1997). c- erbB-
2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepato-
Gastroenterology, 44, pp 294-298. 
Tsugawa, K; Yonemura, Y; Hirono, Y; Fushida, S; Kaji, M; Miwa, K; Miyazaki, I; Yamamoto, 
H. (1998). Amplification of the c-met, c-erbB-2 and epidermal growth factor 
receptor gene in human gastric cancers: correlation to clinical features. Oncology, 55, 
pp475- 481. 
Nakajima, M; Sawada, H; Yamada, Y; Watanabe, A; Tatsumi, M; Yamashita, J; Matsuda, M; 
Sakaguchi, T; Hirao, T; Nakano, H. (1999). The prognostic significance of 
amplification and overexpression of c-met and c-erbB-2 in human gastric 
carcinomas. Cancer, 85, pp1894- 1902. 
www.intechopen.com
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
158 
Pinto-de-Sousa, J; David, L; Almeida, R; Leitão, D; Preto, JR; Seixas, M; Pimenta, A. (2002). c-
erbB-2 expression is associated with tumor location and venous invasion and 
influences survival of patients with gastric carcinoma. Int J Surg Pathol, 10, pp247- 
256. 
Gurel, S; Dolar, E; Yerci, O; Samli, B; Ozturk, H; Nak, SG; Gulten, M; Memik, F. (1999). The 
relationship between c-erbB-2 oncogene expression and clinicopathological factors 
in gastric cancer. J Int Med Res, 27, pp74- 78. 
Polkowski, W; van Sandick, JW; Offerhaus, GJ; ten Kate, FJ; Mulder, J; Obertop, H; van 
Lanschot, JJ. (1999). Prognostic value of Lauren classification and c-erbB-2 oncogene 
overexpression in adenocarcinoma of the esophagus and gastroesophageal 
junction. Ann Surg Oncol, 6, pp290- 297.  
Yasui, W; Sumiyoshi, H; Hata, J; Kameda, T; Ochiai, A; Ito, H; Tahara, E. (1988). Expression 
of epidermal growth factor in human gastric and colonic carcinomas. Cancer Res, 48, 
pp137- 141. 
Kopp, R; Ruge, M; Rothbauer, E; Cramer, C; Kraemling, HJ; Wiebeck, B; Schildberg, FW; 
Pfeiffer, A. (2002). Impact of epidermal growth factor (EGF) radioreceptor analysis 
on long-term survival of gastric cancer patients. Anticancer Res, 22, pp1161-1167. 
Coyle, WJ; Sedlack, RE; Nemec, R; Peterson, R; Duntemann, T; Murphy, M; Lawson, J. 
(1999). Eradication of Helicobacter pylori normalizes elevated mucosal levels of 
epidermal growth factor and its receptor. Am J Gastroenterol, 94, pp2885- 2889.  
Gamboza- Dominguez, A; Dominguez- Fonseca, C; Quintanilla- Martinez, L; Reyes- 
Gutierrez, E; Green, D; Angles- Angles, A; Busch, R; Hermannstadter, C; Nahrig, J; 
Becker, KF; Becker, I; Hofler, H; Fend, F; Luber, B. (2004). Epidermal growth factor 
receptor expression correlates with poor survival in gastric adenocarcinoma from 
Mexican patients: a multivariate analysis using a standardized 
immunohistochemical detection system. Mod Pathol, 17, pp579-587.  
www.intechopen.com
Gastric Carcinoma - Molecular Aspects and Current Advances
Edited by Prof. Mahmoud Lotfy
ISBN 978-953-307-412-2
Hard cover, 354 pages
Publisher InTech
Published online 15, June, 2011
Published in print edition June, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Gastric cancer is one of the most common tumors worldwide. It has a heterogeneous milieu, where the genetic
background, tumor immunology, oxidative stress, and microbial infections are key players in the multiple
stages of tumorigenesis. These diverse factors are linked to the prognosis of the gastric cancer and the
survival of gastric cancer patients. This book is appropriate for scientists and students in the field of oncology,
gastroenterology, molecular biology, immunology, cell biology, biology, biochemistry, and pathology. This
authoritative text carefully explains the fundamentals, providing a general overview of the principles followed
by more detailed explanations of these recent topics efficiently. The topics presented herein contain the most
recent knowledge in gastric cancer concerning the oncogenic signaling, genetic instability, the epigenetic
aspect, molecular features and their clinical implications, miRNAs, integrin and E-cadherin, carbohydrate-
associated-transferases, free radicals, immune cell responses, mucins, Helicobacter-pylori, neoadjuvant and
adjuvant therapy, prophylactic strategy for peritoneal recurrence, and hepatic metastasis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jolanta Czyzewska (2011). Human Epidermal Growth Factor (Her) in Gastric Cancer, Gastric Carcinoma -
Molecular Aspects and Current Advances, Prof. Mahmoud Lotfy (Ed.), ISBN: 978-953-307-412-2, InTech,
Available from: http://www.intechopen.com/books/gastric-carcinoma-molecular-aspects-and-current-
advances/human-epidermal-growth-factor-her-in-gastric-cancer
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
